Dominik Kiem

Dominik Kiem is a Researcher in the Department of Internal Medicine III - Division of Hematology, Medical Oncology, Hemostaseology, Rheumatology, Infectiology and Oncologic Center. His work focuses on oncology and immunotherapy, with an emphasis on clinical trials, PD-L1 inhibitors, and treatment outcomes for cancers such as head and neck, esophageal, and pancreatic malignancies. Recent studies include evaluating combinatorial immunotherapies and real-world applications of checkpoint inhibitors.

Research interests span cancer biology, immuno-oncology, and targeted therapies. His studies often explore predictive biomarkers, treatment efficacy in second-line therapies, and novel drug delivery systems like liposomal doxorubicin.

Publications highlight clinical trial advancements and real-world data analysis, contributing to evidence-based strategies for palliative care and combination therapies. No scientific awards are explicitly mentioned in the provided texts.